Your browser version may not work well with NCBI's Web applications. More information here...
1: J Comput Aided Mol Des. 1995 Apr;9(2):139-48.Links

PRO-LIGAND: an approach to de novo molecular design. 3. A genetic algorithm for structure refinement.

Westhead DR, Clark DE, Frenkel D, Li J, Murray CW, Robson B, Waszkowycz B.

Proteus Molecular Design Ltd., Macclesfield, Cheshire, U.K.

Recently, the development of computer programs which permit the de novo design of molecular structures satisfying a set of steric and chemical constraints has become a burgeoning area of research and many operational systems have been reported in the literature. Experience with PRO-LIGAND-the de novo design methodology embodied in our in-house molecular design and simulation system PRO-METHEUS-has suggested that the addition of a genetic algorithm (GA) structure refinement procedure can 'add value' to an already useful tool. Starting with the set of designed molecules as an initial population, the GA can combine features from both high- and low-scoring structures and, over a number of generations, produce individuals of better score than any of the starting structures. This paper describes how we have implemented such a procedure and demonstrates its efficacy in improving two sets of molecules generated by different de novo design projects.

PMID: 7608745 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Methotrexate (Rheumatrex® , Trexall® )

    Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments. Methotrexate is also used along with rest, physica...

  • Source: AHFS Consumer Medication Information